We attended the Annual Meeting of the American Society of Clinical Oncology 2017 (ASCO 2017) from June 2 to June 6 in Chicago.
After several years of huge excitement around IO this year’s meeting tone was more muted. IO is real and there are synergistic effects in combinations therapies – just as it was hoped for – but what is missing is better biomarkers in order to figure out which patients will benefit best from what treatments.